BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8384264)

  • 1. Intensive combined modality therapy for limited-stage small-cell lung cancer.
    Elias AD; Ayash L; Frei E; Skarin AT; Hunt M; Wheeler C; Schwartz G; Mazanet R; Tepler I; Eder JP
    J Natl Cancer Inst; 1993 Apr; 85(7):559-66. PubMed ID: 8384264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome.
    Elias A; Ibrahim J; Skarin AT; Wheeler C; McCauley M; Ayash L; Richardson P; Schnipper L; Antman KH; Frei E
    J Clin Oncol; 1999 Apr; 17(4):1175. PubMed ID: 10561176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
    Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
    Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
    Schild SE; Bonner JA; Hillman S; Kozelsky TF; Vigliotti AP; Marks RS; Graham DL; Soori GS; Kugler JW; Tenglin RC; Wender DB; Adjei A
    J Clin Oncol; 2007 Jul; 25(21):3124-9. PubMed ID: 17634491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
    Ihde DC; Deisseroth AB; Lichter AS; Bunn PA; Carney DN; Cohen MH; Veach SR; Makuch RW; Johnston-Early A; Abrams RA
    J Clin Oncol; 1986 Oct; 4(10):1443-54. PubMed ID: 3020181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.
    Humblet Y; Symann M; Bosly A; Delaunois L; Francis C; Machiels J; Beauduin M; Doyen C; Weynants P; Longueville J
    J Clin Oncol; 1987 Dec; 5(12):1864-73. PubMed ID: 2824708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study.
    Aisner J; Goutsou M; Maurer LH; Cooper R; Chahinian P; Carey R; Skarin A; Slawson R; Perry MC; Green MR
    J Clin Oncol; 1992 Aug; 10(8):1230-6. PubMed ID: 1321892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
    Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer.
    Elias AD; Ayash L; Skarin AT; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper L; Frei E; Antman KH
    Chest; 1993 Apr; 103(4 Suppl):433S-435S. PubMed ID: 8096454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study.
    Shepherd FA; Ginsberg RJ; Patterson GA; Evans WK; Feld R
    J Thorac Cardiovasc Surg; 1989 Feb; 97(2):177-86. PubMed ID: 2536868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.